Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
VSC
vs
DAX Index
VSC
Over the past 12 months, VSC has underperformed DAX Index, delivering a return of -80% compared to DAX Index's +13% growth.
Stocks Performance
VSC vs DAX Index
Performance Gap
VSC vs DAX Index
Performance By Year
VSC vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
4Sc AG
Glance View
4SC AG is a clinical-stage biopharmaceutical company, which engages in the development of small molecule drugs that target key indications in cancer. The company is headquartered in Planegg, Bayern and currently employs 14 full-time employees. The company went IPO on 2008-02-25. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.